Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Part B: Week 4-Week 12 Clear all
Terminated Phase 1Phase 2 Interventional Results available

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

NCT02906670
View directory record Official record
Conditions
Oncology
Interventions
Sym013
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 7, 2026, 4:26 PM EDT
Active, not recruiting Not applicable Interventional

Mobile Health for Adherence in Breast Cancer Patients

NCT06112613
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Electronic Health Record Review, Health Promotion and Education, Health Telemonitoring, Patient Navigation, Survey Administration, Text Message-Based Navigation Intervention
Other · Procedure · Behavioral
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
499
States / cities
Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 338 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Terminated Phase 1 Interventional

Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT02530502
View directory record Official record
Conditions
Adult Glioblastoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide
Other · Biological · Radiation + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 7, 2026, 4:26 PM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

NCT01705145
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 5 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
16
States / cities
Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Sep 7, 2026, 4:26 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

NCT02204371
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic
Interventions
Pazopanib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 7, 2026, 4:26 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

NCT03493854
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Cyclophosphamide, Doxorubicin, Docetaxel, Paclitaxel, Pertuzumab IV, FDC of Pertuzumab and Trastuzumab SC, Trastuzumab IV, Trastuzumab SC, Surgery, Post-operative Radiotherapy, Hormone Therapy
Drug · Procedure · Radiation
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 7, 2026, 4:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907
View directory record Official record
Conditions
Weight Management
Interventions
GS-4571, Placebo, Omeprazole
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Terminated Phase 2 Interventional Results available

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

NCT03488251
View directory record Official record
Conditions
Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Interventions
MT-3724, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
9
States / cities
Orange, California • Santa Monica, California • Whittier, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Sep 7, 2026, 4:26 PM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147
View directory record Official record
Conditions
IgG4 Related Disease, IgG4-RD
Interventions
elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

NCT03375047
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
MRT5005, Normal saline
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
16
States / cities
Birmingham, Alabama • Denver, Colorado • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

NCT01020006
View directory record Official record
Conditions
Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
Interventions
PCI-27483, Gemcitabine
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • Anaheim, California • Titusville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 7, 2026, 4:26 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

NCT02531633
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 7, 2026, 4:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

NCT07390955
View directory record Official record
Conditions
HIV
Interventions
ePGT121v1-LS (IV), PGDM1400LS (IV), VRC07-523LS (IV), ePGT121v1-LS (SC), PGDM1400LS (SC), VRC07-523LS (SC)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Active, not recruiting Phase 1 Interventional

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

NCT03313778
View directory record Official record
Conditions
Solid Tumors
Interventions
mRNA-4157, Pembrolizumab, SoC Treatment
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

NCT02519348
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tremelimumab, Durvalumab, Bevacizumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Not listed Phase 1Phase 2 Interventional

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

NCT04669587
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
ZB716, Palbociclib
Drug
Lead sponsor
EnhancedBio USA Inc.
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 7, 2026, 4:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.

NCT07090889
View directory record Official record
Conditions
Olmsted Syndrome
Interventions
KM-023, Placebo
Drug
Lead sponsor
Orvida Pharma (formerly Kamari Pharma)
Network
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3463251 in Healthy Participants

NCT03764774
View directory record Official record
Conditions
Healthy
Interventions
LY3463251, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 7, 2026, 4:26 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT05219513
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
RO7443904, Glofitamab, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 7, 2026, 4:26 PM EDT
Terminated Phase 1 Interventional

Study of GS-0272 in Participants With Rheumatoid Arthritis

NCT06031415
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GS-0272, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Glendale, California • Palo Alto, California • Upland, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato® Granisetron Single Dose PK

NCT04200092
View directory record Official record
Conditions
Healthy
Interventions
0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo
Combination Product · Drug · Other
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

NCT01931839
View directory record Official record
Conditions
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor Combination, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
91
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 7, 2026, 4:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3502970 in Healthy Participants

NCT03929744
View directory record Official record
Conditions
Healthy
Interventions
LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 7, 2026, 4:26 PM EDT
Completed Phase 1 Interventional

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

NCT03194932
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy, Azacitidine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 20 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Palo Alto, California • Chapel Hill, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 7, 2026, 4:26 PM EDT